Dermata Therapeutics, Inc. (DRMA) is a Biotechnology company in the Healthcare sector, currently trading at $1.25. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is DRMA = $6 (+380% upside).
Valuation: DRMA trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.01.
Net income is $8M (loss), growing at -52471.3%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $0 against $6.2B equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 4585.32 (strong liquidity). Debt-to-assets is 0%. Total assets: $7.9B.
Analyst outlook: 1 / 1 analysts rate DRMA as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).
